title: [Effects of allitridi capsules on endothelial function and clinical prognosis in coronary artery disease patients with obstructive sleep apnea hypopnea syndrome].
abstract: OBJECTIVE
  To explore the effects of allitridi capsules on endothelial function and clinical prognosis in coronary artery disease (CAD) patients with obstructive sleep apnea hypopnea syndrome (OSAHS).
  
  
  METHODS
  A total of 80 CAD patients with OSAHS were randomly assigned to receive conventional treatment (control, n = 40) and additional allitridi treatment (120 mg/day, n = 40) for 6 months. Another 40 CAD patients without OSAHS and 30 healthy individuals were chosen as controls. Endothelial function was assessed by endothelium dependent flow-mediated dilation (FMD) with high-definition color Doppler ultrasound. Serum nitric oxide (NO) and plasma endothelin-1 (ET-1) levels were determined by enzyme-linked immunosorbent assay (ELISA) and radioimmunoassay. The duration of follow-up was 1 year.
  
  
  RESULTS
  The baseline clinical characteristics were not different between control and allitridi groups (P > 0.05). Compared with CAD patients without OSAHS, FMD and serum NO level were significantly lower ((7.9 ± 1.5)% vs (11.2 ± 2.9)%, P = 0.011 and (71.11 ± 10.62) vs (86.28 ± 11.03) µmol/L, P = 0.007), plasma ET-1 level was markedly higher ((112.34 ± 17.22) vs (89.87 ± 11.56) ng/L, P = 0.025) in CAD patients with OSAHS. At Month 6 post-treatment, FMD and serum NO level were significantly higher ((12.1 ± 3.1)% vs (9.1 ± 1.6)%, P = 0.020 and (105.24 ± 17.01) vs (82.39 ± 11.12) µmol/L, P = 0.001) and plasma ET-1 level in the allitridi group was lower ((77.12 ± 9.65) vs (97.77 ± 11.04) ng/L, P = 0.001) than that in the control group. At Month 12 post-treatment, the incidence of MACE was lower in the allitridi group than that in the control group (8.3% vs 15.8%, P = 0.016).
  
  
  CONCLUSIONS
  Allitridi capsules significantly improved endothelial function in CAD patients with OSAHS.
authors.affiliation: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Xiaomin
authors.initials: X
authors.lastname: Nie
authors.affiliation: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Lixiao
authors.initials: L
authors.lastname: Su
authors.affiliation: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Yajing
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Xiping
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
authors.forename: Mingyu
authors.initials: M
authors.lastname: Shang
authors.affiliation: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. Email: weiyongxiang@sina.com.
authors.forename: Yongxiang
authors.initials: Y
authors.lastname: Wei
mesh_terms: D000498:Allyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D002214:Capsules; D003324:Coronary Artery Disease / Q000150:complications / Q000188:drug therapy*; D019332:Endothelin-1; D004730:Endothelium, Vascular / Q000187:drug effects*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D009569:Nitric Oxide; D011379:Prognosis; D020181:Sleep Apnea, Obstructive / Q000150:complications*; D013440:Sulfides / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000498:Allyl Compounds; D002214:Capsules; D019332:Endothelin-1; D013440:Sulfides; C042577:diallyl trisulfide; D009569:Nitric Oxide